In a cramped lab at the Hospital for Special Surgery in New York, Dr. Laura Donlin and her team peered into the tangled architecture of joint tissue from rheumatoid arthritis (RA) patients—and found something unexpected: a rogue crew of immune cells building, not just inflaming. These cells, called SPP1ʰⁱ macrophages, were nesting in fibrin-rich pockets within the synovium, the joint lining, where they were quietly orchestrating a destructive form of tissue overgrowth once thought to be purely a side effect of inflammation. Now, their discovery, published in Science Translational Medicine, is rewriting the story of how RA progresses—and how it might one day be stopped.
For decades, rheumatoid arthritis has been treated as an inflammatory disease, with therapies aimed at calming the immune system’s attack on the joints. But while inflammation explains pain and swelling, it doesn’t fully account for pannus—the invasive, tumor-like tissue that eats away at cartilage and bone. This new research reveals a parallel engine driving RA: a tissue repair system gone rogue. Using spatial transcriptomics to map gene activity directly in human joint samples, the HSS team found that SPP1ʰⁱ macrophages break down fibrin scaffolds (a protein usually involved in clotting) and, in the process, signal nearby fibroblasts to multiply and lay down new matrix. The result? Uncontrolled tissue expansion that mimics wound healing—but with no wound to heal.
What’s more, this process operates largely independent of classic inflammatory pathways. That’s a paradigm shift. "This work suggests that rheumatoid arthritis is not only driven by inflammation but also by dysregulated tissue repair processes," Donlin said. Her team found that these macrophages thrive in niches rich in fibrin, interacting closely with fibroblasts primed for proliferation—creating a self-sustaining cycle of growth. Unlike fibrosis, where dense collagen builds up, this is “pro-generative” remodeling: dynamic, cellular, and destructive. Crucially, the study links these cells to IL-6 signaling, helping explain why drugs like tocilizumab, which block IL-6, show strong effects in some RA patients.
The implications stretch beyond arthritis. SPP1ʰⁱ macrophages have been spotted in interstitial lung disease, lupus, cancer, and even traumatic injuries—suggesting this fibrin-dependent repair mechanism may be a universal, if sometimes dangerous, tool in the body’s healing arsenal. By uncovering this pathway, the HSS team isn’t just offering a new drug target for RA—they’re illuminating a fundamental biological process that, when misfired, can cause damage across the body.
Now, the focus shifts to precision. If future therapies can disrupt the SPP1ʰⁱ macrophage-fibroblast dialogue without halting healthy repair, patients might one day avoid joint destruction without broad immunosuppression. For the 1.3 million Americans living with RA, that’s not just progress—it’s hope, rebuilt from the ground up.